Tilsner V, Witte G
Abt. für Blutgerinnungsstörungen, Universitätsklinik, Hamburg-Eppendorf, FRG.
Haemostasis. 1988;18 Suppl 1:139-56. doi: 10.1159/000215849.
The accepted correct procedure for treating occlusive arterial diseases includes surgical disobstruction, CL as well as PTA. Combined non-surgical strategies are effective in about 60% of these patients. However, a high risk of rethrombosis despite from the prophylaxis with anticoagulants like heparin or antiplatelet drugs like ASA is proven, especially in patients with multi-segmental stenosis as well as in patients with extensive narrowing of the arteries. In these cases primary lesions (endangitis obliterans) or secondary lesions of the endothelium cause local depletion of plasminogen in the endothelium. Independent of the method used for reopening the vessel in these patients, a significant progression of the vessel disease and a high rethrombosis rate during longterm follow-up is observed. These results lead us to apply plasminogen locally to decrease the rate of rethrombosis. In patients suffering from stage III-IV (La Fontaine) including patients with multi-segmental stenosis as well as extended narrowing of the artery, PTA in combination with CL was performed. The catheter was placed as near as possible to the thrombus. In some cases the 'fibrinolyticum' could be injected directly into the thrombus. In these cases a bolus of 4,000 U/ml was locally infused, otherwise 1.0-1.5 million U urokinase per 24 hrs. were locally infused with heparin. In 28% (22 patients) no sufficient clinical response occurred using this combined therapy and plasminogen was applied locally. The following criteria supported our decision to include the patients in this study: 1. Insufficient response occurring after 12-24 hrs. of local infusion. 2. Following 6 bolus injections no reopening of the vessel occured within 60 minutes or the clinical response was insufficient due to rethrombosis. 3. Insufficient effects of lysis therapy after 2 hours and contraindication for a systemic fibrinolytic therapy (e.g. hypertension, age, etc.). 1,000 U plasminogen per ml were infused locally or 2,000 U up to 5,000 U plasminogen (in 5 to 10 ml 0.9% saline) were infused slowly (2-4 minutes infusion time) into the catheter in these patients 10 minutes after unsuccessful treatment with local urokinase therapy. Five minutes after administering plasminogen local intraarterial fibrinolytic therapy with urokinase was continued. No severe side effects due to this therapy were observed, although some patients suffered from acute pains in the peripheral segments of the arteries occurring immediately after infusion of plasminogen. In 16 of 22 patients a complete recanalization occurred and in 3 patients a satisfying clinical improvement was observed.(ABSTRACT TRUNCATED AT 400 WORDS)
治疗闭塞性动脉疾病公认的正确程序包括手术疏通、腔内激光治疗(CL)以及经皮腔内血管成形术(PTA)。联合非手术策略在约60%的此类患者中有效。然而,已证实尽管使用肝素等抗凝剂或阿司匹林等抗血小板药物进行预防,但再血栓形成的风险仍然很高,尤其是在多节段狭窄患者以及动脉广泛狭窄的患者中。在这些情况下,原发性病变(血栓闭塞性脉管炎)或内皮的继发性病变会导致内皮中纤溶酶原局部耗竭。无论在这些患者中使用何种方法重新开通血管,在长期随访中都观察到血管疾病的显著进展和高再血栓形成率。这些结果促使我们局部应用纤溶酶原以降低再血栓形成率。对于患有III-IV期(拉方丹分期)的患者,包括多节段狭窄以及动脉广泛狭窄的患者,进行了PTA联合CL治疗。将导管尽可能靠近血栓放置。在某些情况下,“纤维蛋白溶解剂”可直接注入血栓中。在这些情况下,局部注入4000 U/ml的大剂量药物,否则每24小时局部注入100 - 150万U尿激酶并联合肝素。在28%(22例患者)中,使用这种联合治疗未出现足够的临床反应,于是局部应用纤溶酶原。以下标准支持我们将这些患者纳入本研究的决定:1. 局部输注12 - 24小时后反应不足。2. 在6次大剂量注射后,60分钟内血管未重新开通,或者由于再血栓形成临床反应不足。3. 溶栓治疗2小时后效果不佳且存在全身溶栓治疗的禁忌证(如高血压、年龄等)。在局部尿激酶治疗失败10分钟后,向这些患者的导管内局部输注每毫升1000 U纤溶酶原,或缓慢(输注时间2 - 4分钟)注入2000 - 5000 U纤溶酶原(溶于5 - 10 ml 0.9%盐水中)。在给予纤溶酶原5分钟后,继续用尿激酶进行局部动脉内溶栓治疗。尽管一些患者在注入纤溶酶原后立即出现动脉外周段急性疼痛,但未观察到该治疗引起的严重副作用。22例患者中有16例实现了完全再通,3例患者观察到临床状况有令人满意的改善。(摘要截断于400字)